We use machine learning to optimise and develop the current drug discovery process. Our world-first computational technique means we can discover new antibodies, faster and better.
Co-founded in 2017 by engineers Murat Tunaboylu and Ben Holland, our team is dedicated to engineering the future of drug development to change the course of people's lives. We are passionate about what we do and the impact our discoveries will have on patients across the globe. Based in Cardiff, our expert team spans structural biology, machine learning and medicine - and together, we are always striving for that next breakthrough in drug discovery.
When you have too many antibody-antigen binding options to choose from, we can provide targeted options so you can focus on testing safely in the knowledge that you have the cream of the crop in front of you.
When you struggle to find sufficient binders, we can recover potential binders that are so often missed by conventional methods.
When you have some binders that bind but are deficient in other aspects, we can generate new variants to expand your options.
Everything we do here at Antiverse challenges the status quo. We work in an industry where there are more antibodies than there are stars in the universe, so that makes our work fiercely exciting and fun. We like to think differently and are fortunate to have a brilliant team based in Cardiff. It’s our mission to make a difference to people’s lives that drives us.
Everything we do here at Antiverse challenges the status quo. We work in an industry where there are more antibodies than there are stars in the universe, so that makes our work fiercely exciting and fun. We like to think differently and are fortunate to have a brilliant team based in Cardiff. It’s our mission to make a difference to people’s lives that drives us.
Antiverse collaborates with a top 20 pharma company to identify antibody drug candidates using AI Augmented Drug Discovery platform.
Antiverse’s platform accurately identified diverse and rare antibodies.
Project demonstrates potential of Antiverse’s platform to reduce time and costs associated with antibody drug discovery.
Antiverse, a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling £1.4 million ($2 million USD), comprising new investment and match funding from Innovate UK, the UK’s innovation agency.
The programme is designed for startups with well defined business models and technical capability, in addition to access to computation power, the programme provides the frameworks and expertise to accelerate the responsible and ethical development and application of AI across industry.
We’ve been selected as one of Hello Tomorrow’s Top 500 deeptech startups from over 4,500 applications from 119 countries!
It is our pleasure to share that Antiverse has closed its Seed Round with well-known, highly regarded investors from software and biotech industries. The capital and the new connections acquired at this round will give Antiverse the chance to bring its machine learning model to the next level.
